Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Other Operating Expenses (2023 - 2024)

Historic Other Operating Expenses for Cartesian Therapeutics (RNAC) over the last 2 years, with Q4 2024 value amounting to $7.6 million.

  • Cartesian Therapeutics' Other Operating Expenses rose 96746.48% to $7.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 96746.48%. This contributed to the annual value of $7.6 million for FY2024, which is 96746.48% up from last year.
  • According to the latest figures from Q4 2024, Cartesian Therapeutics' Other Operating Expenses is $7.6 million, which was up 96746.48% from $710000.0 recorded in Q4 2023.
  • Cartesian Therapeutics' Other Operating Expenses' 5-year high stood at $7.6 million during Q4 2024, with a 5-year trough of $710000.0 in Q4 2023.